Jan Öhrstrom

Chair

Jan Öhrstrom

Chair

Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies (Novo Nordisk, ZymoGenetics inc). Proven track record with product approvals, financing, M&A and IPO at Nasdaq (ZGEN) and Euronext (BUP.PA).  Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through $240Mill M&A with The Medicines Company after successful Phase 3 completion and approvals in EU and US. Chairman of the Board at Biomup SA, GTXmedical BV and Blaze Biosciences Inc. M.D from Univ of Copenhagen followed by six years surgical training. Dr Öhrström is a Danish citizen and resident in the Netherlands.

Alexander Vos

Executive member

Alexander Vos

Executive member

Alexander Vos has 25 years of leadership experience in the biotech industry. After five years at the pharmaceutical practice of McKinsey&Co, he continued at Genzyme Therapeutics Europe, holding several executive positions, including global responsibility for the Genzyme/Pharming JV to develop an ERT for Pompe’s Disease. From 2000 to 2004, Mr. Vos served as CEO of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Subsequently he joined PAION AG, a publicly listed, clinical stage biopharma company based in Aachen (Germany) as a Member of the Management Board (“Vorstand”), deputy-CEO and COO. In 2010 he became the CEO of PharmaCell BV and helped turn it into the leading European CMO for cell and gene therapy. PharmaCell was sold to Lonza in May 2017 creating a successful exit for investors. He currently serves on the Board of Directors of several privately held biotechnology companies. Mr. Vos holds a MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University.

Casper Breum

Member

Casper Breum

Member

John de Koning

Member

John de Koning

Member

Oskar Slotboom

Member

Oskar Slotboom

Member

Oskar has a broad biotech and business background and is currently partner at BioGeneration Ventures. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first in business development and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration Oskar was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.

Oskar has a degree in chemical engineering from Twente University and holds a MBA from INSEAD.

Oskar serves on several boards of companies in BioGeneration’s portfolio.

Guillem Laporta

Member

Guillem Laporta

Member

 

 

Roel Bulthuis

Member

Roel Bulthuis

Member
This website uses functional and analytical cookies. Accept Deny